restructuring
Korro Bio Lays Off 20% of Workforce to Extend Runway for Genetic Medicine Trials and Novo Nordisk Partnership
Korro Bio; layoffs; biotech; genetic medicine; RNA editing; KRRO-110; Novo Nordisk; clinical trial funding; restructuring; AATD
Schrödinger Lays Off 60 Staffers Amid Economic Uncertainty
Schrödinger; layoffs; biotech; workforce reduction; economic conditions; cost cutting; restructuring
Prime Medicine CEO Exits Amidst Layoffs and Restructuring as Sole Clinical Gene Therapy Shelved
Prime Medicine; CEO exit; gene therapy; layoffs; restructuring; biotech; PM359; prime editing; clinical trial; pipeline pivot
Bayer Restructuring Cuts 2,000 Jobs, Thins Management Layers in 2025
Bayer; restructuring; job cuts; management layers; layoffs; Frankfurt plant closure; pharmaceutical industry
AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil
Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs
Takeda announces handful of pipeline cuts in effort to pivot resources
Takeda, pipeline, restructuring, Solid Neoplasm, pivot resources
FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce
FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy
Biopharma Layoff Trends in Q1 2025 and Outlook for Q2
Biopharma layoffs, Q1 2025 layoffs, biotech job cuts, pharma workforce reductions, restructuring, patent cliffs, regulatory challenges, Q2 layoff forecast, pharmaceutical employment trends, biopharma industry changes.
Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges
Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges
Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth
Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments